About AVT
Browse Articles
Customer Services

Browse Articles

Additional files for manuscripts published before Volume 14 Issue 6 can be found via the abstract link.

Articles published electronically ahead of print and our archive from Volume 4 Issue 1 to Volume 21 Issue 4 can be found below. Articles published earlier will be made available as soon as possible. If you require an article that cannot be found below, please contact the Editorial Office.

Currently showing:   
Displaying 2007 results:

Case report

Bull’s eye maculopathy in an HIV-positive patient receiving ritonavir

Lemuel Non, Abdallah Jeroudi, Bradley T Smith, Shadi Parsaei

Antiviral Therapy 2016; 21:365-367

Short communication

Cerebrospinal fluid and plasma lopinavir concentrations and viral response in virologically suppressed patients switching to lopinavir/ritonavir monotherapy once daily

Juan M Tiraboschi, Hernando Knobel, Arkaitz Imaz, Judith Villar, Elena Ferrer, Maria Saumoy, Alicia González, Nerea Rozas, Antonia Vila, Jordi Niubó, Jordi Curto, Daniel Podzamczer

Antiviral Therapy 2016; 21:359-363

Short communication

Safety of darunavir and atazanavir in HIV-infected children in Europe and Thailand

The European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC)† Study Group in EuroCoord

Antiviral Therapy 2016; 21:353-358

Original article

Impact of low-level viraemia on virological failure in HIV-1-infected patients with stable antiretroviral treatment

Jordi Navarro, Estrella Caballero, Adrian Curran, Joaquin Burgos, Inma Ocaña, Vicenç Falcó, Ariadna Torrella, Mercè Pérez, Esteban Ribera, Manuel Crespo

Antiviral Therapy 2016; 21:345-352

Original article

Sustained immune control in HBeAg-positive patients who switched from entecavir therapy to pegylated interferon-α2a: 1 year follow-up of the OSST study

Meifang Han, Jiaji Jiang, Jinlin Hou, Deming Tan, Yongtao Sun, Mianzhi Zhao, Qin Ning

Antiviral Therapy 2016; 21:337-344

Original article

Efficacy and safety of a switch to rilpivirine-based regimens in treatment-experienced HIV-1-infected patients: a cohort study

Sandrine Gazaignes, Matthieu Resche-Rigon, Caroline Gatey, Chloe Yang, Blandine Denis, Julien Fonsart, Kristell Desseaux, Michel Guionie, Willy Rozenbaum, Constance Delaugerre, Jean-Michel Molina

Antiviral Therapy 2016; 21:329-336

Original article

Assessment of etravirine resistance in HIV-1-infected paediatric patients using population and deep sequencing: final results of the PIANO study

Lotke Tambuyzer, Kim Thys, Annemie Hoogstoel, Steven Nijs, Frank Tomaka, Magda Opsomer, Sandra De Meyer, Johan Vingerhoets

Antiviral Therapy 2016; 21:317-327

Original article

Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice

Hiromi Kan, Nobuhiko Hiraga, Michio Imamura, C Nelson Hayes, Takuro Uchida, Eisuke Miyaki, Masataka Tsuge, Hiromi Abe, Hiroshi Aikata, Daiki Miki, Hidenori Ochi, Yuji Ishida, Chise Tateno, Kazuaki Chayama

Antiviral Therapy 2016; 21:307-315

Original article

Modelling the interaction between danoprevir and mericitabine in the treatment of chronic HCV infection

Laetitia Canini, Jeremie Guedj, Anushree Chatterjee, Annabelle Lemenuel-Diot, Patrick F Smith, Alan S Perelson

Antiviral Therapy 2016; 21:297-306

Original article

Effects on vitamin D, bone and the kidney of switching from fixed-dose tenofovir disoproxil fumarate/emtricitabine/efavirenz to darunavir/ritonavir monotherapy: a randomized, controlled trial (MIDAS)

Lisa Hamzah, Juan M Tiraboschi, Helen Iveson, Martina Toby, Christine Mant, John Cason, Keith Burling, Emily Wandolo, Isabelle Jendrulek, Chris Taylor, Fowzia Ibrahim, Ranjababu Kulasegaram, Alastair Teague, Frank A Post, Julie Fox

Antiviral Therapy 2016; 21:287-296

Copyright © Nucleus Global 2016. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.